CMS Proposes to Retire Some SDOH Questions and Refine Drug-Price Data Collections

Two unglamorous CMS forms are doing a surprising amount of policy work in a newly surfaced Federal Register notice. The agency is proposing to remove social-needs questions from one collection after stakeholders flagged overlap with other screening work, while revising a separate manufacturer data collection tied to Medicare’s drug-price negotiation program.

### What It Is

The notice is a Paperwork Reduction Act request, now on Federal Register public inspection and slated for publication August 21. That means CMS is seeking public comment on proposed information-collection changes; it is not issuing a final payment policy or rewriting the drug-negotiation statute by way of a forms update. The notice covers two established CMS collections: CMS-2728 (OMB control number 0938-0046) and CMS-10110 (0938-0921).

### What’s Changing

For CMS-2728, a one-time admission form, CMS would delete questions about social determinants of health vulnerabilities. The agency says stakeholders identified duplication with quality-improvement-program screening workflows. The notice also describes a proposal to revise the average-sales-price data collection used to support manufacturer effectuation of the Maximum Fair Price for selected drugs payable under Part B.

Those are distinct pieces of administrative machinery, but both illustrate the same governing instinct: if an agency needs information, it must still explain why it needs this particular information, through this particular form, from these particular people. Bureaucracy, occasionally, is allowed to notice it has made the same person answer the same question twice.

### Why It Matters

For patients with kidney failure, removal of SDOH questions from CMS-2728 would shift where certain vulnerability information is collected, not make those needs disappear. CMS’s stated rationale is duplication, so the relevant question for commenters is whether the other screening processes reliably capture the same information and make it usable in care and quality-improvement work.

The Part B change matters for a different reason. Medicare drug negotiation depends on operational data that manufacturers can supply and CMS can use to administer Maximum Fair Prices for selected drugs. CMS is not proposing a new price here; it is proposing a revision to the underlying collection. Still, the details of a data definition can become policy’s smallest, most durable footnote.

CMS says commenters will have 60 days after publication to weigh in. Read the CMS notice on Federal Register public inspection (https://www.federalregister.gov/public-inspection/2026-17128/agency-information-collection-activities-proposals-submissions-and-approvals).